PsyRX CNS Bio-Tech Ltd (PSRX)

Overview

PsyRX CNS Bio-Tech Ltd is a cutting-edge pharmaceutical biotechnology company dedicated to innovating combination therapies aimed at treating psychiatric and neurological disorders. Established in 2019 and based in Rishon LeZion, Israel, the firm is particularly active in addressing the challenges of treatment-resistant depression. PsyRX's flagship program uniquely pairs an FDA-approved SSRI antidepressant with micro-doses of ibogaine, a central nervous system stimulant, delivered in a once-daily oral formulation. This combination is engineered to foster neuroplasticity, ultimately enhancing the efficacy of depression treatments.

In addition to its drug development focus, PsyRX boasts proprietary manufacturing technologies that produce pharmaceutical-grade active pharmaceutical ingredients (APIs), including ibogaine and psilocybin. By employing advanced bioreactor technology and semi-synthetic methods derived from botanical sources such as the Voacanga Africana plant, PsyRX adopts a dual-revenue model that facilitates the development of its psychiatric medications while simultaneously providing high-quality, rare APIs to other pharmaceutical companies and research entities.

Products and Services

• Combination Therapy for Depression:

  The lead program integrates an FDA-approved SSRI antidepressant with a micro-dose of ibogaine, aimed specifically at individuals with treatment-resistant depression. This innovative approach seeks to enhance neuroplasticity, ultimately aiming for improved mental health outcomes.

• Active Pharmaceutical Ingredients (APIs) Manufacturing:

  PsyRX has developed proprietary technology for the manufacturing of pharmaceutical-grade APIs, including ibogaine and psilocybin. This process utilizes bioreactor technology alongside semi-synthetic production methods sourced from plants like Voacanga Africana, ensuring the highest quality of ingredients.

• High-Quality API Supply:

  Beyond its internal development, PsyRX supplies rare and high-quality APIs to other pharmaceutical companies and research institutions. This service supports a wider spectrum of mental health research and therapeutic advancements in the industry.

• Research and Development Support:

  PsyRX offers support for collaborative research and development projects, leveraging its expertise in biotechnology and psychiatric medicine. This assistance helps partner organizations create effective and innovative treatment options for various mental health conditions.